tetano
Editor, Senior Moderator
Am J Epidemiol
. 2021 Apr 13;kwab109.
doi: 10.1093/aje/kwab109. Online ahead of print.
Safety of Tenofovir Disoproxil Fumarate (TDF) for Pregnant Women facing the COVID-19 Pandemic
Sonia Hernandez-Diaz[SUP] 1 [/SUP], Brian T Bateman[SUP] 2 3 [/SUP], Loreen Straub[SUP] 2 [/SUP], Yanmin Zhu[SUP] 2 [/SUP], Helen Mogun[SUP] 2 [/SUP], Michael Fischer[SUP] 2 [/SUP], Krista F Huybrechts[SUP] 2 [/SUP]
Affiliations
Abstract
We assessed the teratogenicity of tenofovir, a human immunodeficiency virus (HIV) drug similar to remdesivir currently being evaluated for the treatment of coronavirus disease 2019 (COVID-19). Using US Medicaid Analytic Extract (MAX) claims data (2000-2014), we identified a population-based pregnancy cohort of women with HIV who filled ?1 prescription for antiretroviral therapies (ART) during the first trimester. Women on tenofovir disoproxil fumarate (TDF) were compared with women receiving ART without TDF. Major malformations were identified by ICD-9 codes using validated algorithms. Relative risks (RR) and 95% confidence intervals (CI) were estimated using propensity score (PS) stratification to control for potential confounders. We incorporated the results into prior knowledge by conducting a systematic literature review and a meta-analysis. Major congenital malformations were diagnosed in 37 out of 866 (4.27%) infants exposed to TDF and 38 out of 1,020 (3.73%) infants exposed to ART other than TDF; the adjusted RR was 1.21 (95% CI 0.77 to 1.90). Estimates for specific malformations were imprecise. The pooled RR from the meta-analysis with six prior studies was 0.88 (0.75 to 1.03). Based on evidence accumulated in patients with HIV, first trimester TDF use does not increase the risk of major congenital malformations overall in the newborn compared to other ART.
Keywords: COVID-19; HIV; TDF; Tenofovir; malformations; pregnancy.
. 2021 Apr 13;kwab109.
doi: 10.1093/aje/kwab109. Online ahead of print.
Safety of Tenofovir Disoproxil Fumarate (TDF) for Pregnant Women facing the COVID-19 Pandemic
Sonia Hernandez-Diaz[SUP] 1 [/SUP], Brian T Bateman[SUP] 2 3 [/SUP], Loreen Straub[SUP] 2 [/SUP], Yanmin Zhu[SUP] 2 [/SUP], Helen Mogun[SUP] 2 [/SUP], Michael Fischer[SUP] 2 [/SUP], Krista F Huybrechts[SUP] 2 [/SUP]
Affiliations
- PMID: 33847737
- DOI: 10.1093/aje/kwab109
Abstract
We assessed the teratogenicity of tenofovir, a human immunodeficiency virus (HIV) drug similar to remdesivir currently being evaluated for the treatment of coronavirus disease 2019 (COVID-19). Using US Medicaid Analytic Extract (MAX) claims data (2000-2014), we identified a population-based pregnancy cohort of women with HIV who filled ?1 prescription for antiretroviral therapies (ART) during the first trimester. Women on tenofovir disoproxil fumarate (TDF) were compared with women receiving ART without TDF. Major malformations were identified by ICD-9 codes using validated algorithms. Relative risks (RR) and 95% confidence intervals (CI) were estimated using propensity score (PS) stratification to control for potential confounders. We incorporated the results into prior knowledge by conducting a systematic literature review and a meta-analysis. Major congenital malformations were diagnosed in 37 out of 866 (4.27%) infants exposed to TDF and 38 out of 1,020 (3.73%) infants exposed to ART other than TDF; the adjusted RR was 1.21 (95% CI 0.77 to 1.90). Estimates for specific malformations were imprecise. The pooled RR from the meta-analysis with six prior studies was 0.88 (0.75 to 1.03). Based on evidence accumulated in patients with HIV, first trimester TDF use does not increase the risk of major congenital malformations overall in the newborn compared to other ART.
Keywords: COVID-19; HIV; TDF; Tenofovir; malformations; pregnancy.